Cancer profiling market seen rising to $25.62 billion by 2030

The Business Research Company says the global cancer profiling market grew to $16.67 billion in 2026 and is projected to reach $25.62 billion by 2030, driven by precision medicine, liquid biopsy adoption and oncology diagnostics investment. North America led the market in 2025, while the report highlights broader use of genomic testing and AI-assisted interpretation.

Why it matters: - Cancer profiling is becoming a core tool in personalized oncology because it helps identify genetic and molecular changes that can shape treatment decisions. - The market’s growth reflects rising cancer incidence, wider use of molecular diagnostics and expanding demand for early detection. - The report’s forecast suggests more hospitals, labs and cancer-care teams will need advanced profiling workflows in the next several years.

What happened: - The Business Research Company published a new global cancer profiling market report on Nov. 6, 2026. - The report estimates the market rose from $15 billion in 2025 to $16.67 billion in 2026. - The report projects the market will reach $25.62 billion by 2030. - The company says the market is advancing as medical diagnostics evolve and as interest grows in personalized cancer treatment and early detection.

The details: - Cancer profiling tests analyze the genetic makeup of tumor cells. - The tests identify molecular or genetic alterations, including gene mutations and changes in tumor DNA. - That information helps clinicians tailor cancer treatment strategies more effectively. - The report links historical growth to rising cancer incidence, more molecular diagnostics laboratories, early adoption of genomic testing in oncology, growth in research-focused cancer profiling and broader availability of diagnostic platforms. - The forecast period is expected to benefit from stronger demand for precision medicine. - Wider use of companion diagnostics is another cited driver. - Liquid biopsy technologies are expected to see broader adoption. - Investment in oncology diagnostics is increasing. - Cancer profiling is moving further into routine clinical workflows. - The report points to rising adoption of next-generation sequencing-based profiles, comprehensive genomic panels, AI-powered data interpretation, personalized oncology diagnostics and early molecular detection. - North America held the leading market position in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report offers market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - A free sample is available here. - The full report is available here.

Between the lines: - The report frames cancer profiling as part of a broader shift from one-size-fits-all oncology toward data-driven treatment selection. - The emphasis on NGS, liquid biopsy and AI interpretation suggests the market is moving toward faster, more comprehensive and more clinically integrated testing. - Regional leadership by North America indicates the market is still anchored in mature diagnostics infrastructure, even as global demand broadens.

What's next: - The report expects the strongest gains through 2030 to come from precision medicine adoption, companion diagnostics and expanding oncology use cases. - Continued growth in cancer incidence should keep pressure on health systems to expand profiling capacity. - More routine use of genomic testing and molecular detection is likely to support further commercialization of profiling platforms. - Contact details and social links provided in the release point readers to The Business Research Company for additional information and distribution updates.